Statistics from Altmetric.com
With the arrival of SARS-CoV-2, it was asked whether our patients with immune-mediated inflammatory disorders, or who had an organ transplantation (IMDT patients) and/or use immunosuppressive medication (imed) are more susceptible to SARS-CoV-2 infection and/or a severe COVID-19 disease course. In the earliest reports on COVID-19, such patients were rarely described. Most reports were retrospectively collected, in various case series or cohorts without a control group.1–3 The Infection and Immunomodulation Inventory Initiative cohort study was started 10 March 2020 to prospectively register self-reported periods of illness with COVID-19-like symptoms (CLS) (see questionnaire in online supplemental table 1) and compare these between IMIDT patients with and without imed and controls as selected from the hospital database of the Leiden University Medical Center in March 2020. Patients were defined as being in outpatient care at the outpatient clinic for rheumatology, gastroenterology, pulmonology and/or nephrology and having an autoinflammatory or autoimmune disease or having had a solid organ transplantation with or without imed (verified from the medical records after participant’s informed consent). Controls were persons who had visited these outpatient clinics in the previous 3 years and were discharged but did not have an IMIDT.
Of the 8670 individuals approached, 2110 with IMIDT and 1067 controls agreed to participate (see baseline characteristics in online supplemental table 2 and differences between the non-repliers and repliers/participants in online supplemental table 3). The most prevalent diagnoses among the participants from the IMIDT group were ulcerative colitis, Crohn’s disease and seropositive rheumatoid arthritis (see online supplemental table 4). Between March and July 2020, 554 (33%) IMIDT patients and 299 (35%) controls recorded an illness episode with at least one symptom, mostly mild with a median (IQR) duration of 4 (3–6) days in both IMIDT patients and controls. Sixteen (6%) IMIDT patients with imed, 8 (3%) IMIDTs without imed and 5 (2%) controls were hospitalised with CLS (p=0.8). Logistic regression analysis showed that female gender (OR 1.45, 95% CI 1.15 to 1.82), lung disease (OR 1.50, 95% CI 1.20 to 1.88) and wearing a face mask (then not yet mandatory) (OR 1.42, 95% CI 1.13 to 1.77) were independently associated with a higher risk of experiencing CLS, whereas older age and use of imed were associated with a lower risk (see table 1).
Thus, we found a similar incidence of CLS in IMIDT patients (with or without imed) and controls. However, IMIDT patients on imeds with CLS had a slightly higher risk to be admitted to hospital, which may suggest worse symptom severity or an estimated greater risk of deterioration. We collected only self-reported symptoms mostly for logistical reasons. With 22% of participants reporting CLS, we may have overestimated the occurrence of COVID-19 and also included symptoms of influenza (season ended in March) and common colds, which, in turn, may have been over-reported during the anxious times of the ‘first wave’ of COVID-19. But since SARS-CoV-2 infection often results in mild influenza like symptoms only, we may in fact have come closer to the true infection rate than what has been reported in earlier observations based on hospitalisations and testing of worse cases.
A relatively low response rate (37%) to our invitation to participate in this study means that there is a possibility of selection bias, the effect of which we cannot estimate.
In conclusion, between March and July 2020, IMIDT patients, whether or not taking imeds, did not show an increased risk of reported CLS compared with controls. In our population, continuing immunosuppressant drugs as long as not ill, while following the Dutch COVID-19 rules, appears to be safe.
The study protocols of IENIMINI cohort study was approved by the Medical Ethics Committee Leiden Delft Den Haag (LDD).
Handling editor Josef S Smolen
Contributors Concept and design: LvO and CFA. Acquisition of data: LvO, CFA, MKN, YKOT and AEM-dJ. Analysis and interpretation: LvO, CFA, MKN, YKOT, AEM-dJ and TWJH. Drafting the manuscript: LvO and CFA. Revising the manuscript critically: MKN, YKOT, AEM-dJ and TWJH. All authors read and approved the final manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests AEM-dJ reports personal fees from Janssen, grants and personal fees from Takeda, personal fees from Galapogos, grants from Nestle and grants from Norgine outside the submitted work.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.